hbsag antibody  (ATCC)

Journal: PLOS One

Article Title: Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage

doi: 10.1371/journal.pone.0340023

Figure Lengend Snippet: HepG2.2.15.7 cells (n = 3) and HBV-inoculated HepaSH cells (1000 GEq/cell, n = 4) were treated with 1 μM auranofin. (A) HBsAg levels in the supernatant and cell viability of HepG2.2.15.7 cells treated with various concentrations of auranofin. (B) HBsAg, HBeAg, and HBV DNA levels in the supernatant and intracellular pgRNA and HBV DNA levels in HepG2.2.15.7 cells treated with or without auranofin. (*: p < 0.05). (C) Western blotting and band quantification of intracellular HBs proteins in HepG2.2.15.7 cells treated with or without auranofin. (D) HBsAg, HBeAg, and HBV DNA levels in the supernatant and intracellular pgRNA, HBV DNA and cccDNA levels in HBV-inoculated HepaSH cells treated with or without auranofin. (*: p < 0.05). (E) Western blotting and band quantification of intracellular HBs proteins in HBV-inoculated HepaSH cells treated with or without auranofin.

Article Snippet: The primary antibodies used were against JNK (#9258), eIF2 α (#5324), IRE1 α (#3294), PERK (#3192), CHOP (#2895) (Cell Signaling Technology, Danvers, MA, USA), pIRE1 α (NB100–2323; Novus Biotechnology, Centennial, CO, USA), beta actin (A5316; Merck KGaA, Darmstadt, Germany), and HBsAg (Bs-1557G Bioss (Woburn, MA, USA) for the HepG2.2.15.7 cell samples and NB100–62652 (Novus Biologicals, Centennial, CO, USA) for the HepaSH cell samples.

Techniques: Western Blot

Journal: bioRxiv

Article Title: HEPLISAV-B Breaks Immune Tolerance and Induces HBV Control via CD4 T Cell-Dependent Mechanisms in a Chronic Hepatitis B Mouse Model

doi: 10.64898/2026.03.13.711721

Figure Lengend Snippet: ( A ) Experimental design of Montanide-adjuvanted HBsAg plus DNA vaccination. ( B ) Plasma HBV DNA by qPCR. Plasma ( C ) HBsAg and ( D ) anti-HBs IgG by ELISA. ( E ) Hepatic immunofluorescence staining of HBsAg and HBcAg with ( F,G ) quantification. Images were acquired at 20x. Data are mean ± SEM. Statistics: two-way ANOVA with Tukey post hoc test.

Article Snippet: For histological and immunofluorescence analyses, formalin-fixed, paraffin-embedded mouse liver sections (5 μm) were stained with hematoxylin and eosin (H&E) or subjected to antigen retrieval and immunostained with anti-HBs (BIOSYNTH, #20-HR20) and anti-HBc (ZETA Corp, #Z2085RL-R) antibodies, followed by Alexa Fluor 488–conjugated anti-rabbit secondary antibody (1:500; Invitrogen).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining

Journal: bioRxiv

Article Title: HEPLISAV-B Breaks Immune Tolerance and Induces HBV Control via CD4 T Cell-Dependent Mechanisms in a Chronic Hepatitis B Mouse Model

doi: 10.64898/2026.03.13.711721

Figure Lengend Snippet: ( A ) Experimental design with three HEPLISAV-B dose levels. ( B ) Plasma anti-HBs IgG measured by ELISA over 12 weeks. Data are mean ± SEM. Statistics: two-way ANOVA with Tukey post hoc test.

Article Snippet: For histological and immunofluorescence analyses, formalin-fixed, paraffin-embedded mouse liver sections (5 μm) were stained with hematoxylin and eosin (H&E) or subjected to antigen retrieval and immunostained with anti-HBs (BIOSYNTH, #20-HR20) and anti-HBc (ZETA Corp, #Z2085RL-R) antibodies, followed by Alexa Fluor 488–conjugated anti-rabbit secondary antibody (1:500; Invitrogen).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay

Journal: bioRxiv

Article Title: HEPLISAV-B Breaks Immune Tolerance and Induces HBV Control via CD4 T Cell-Dependent Mechanisms in a Chronic Hepatitis B Mouse Model

doi: 10.64898/2026.03.13.711721

Figure Lengend Snippet: ( A ) Plasma anti-HBs IgG levels measured longitudinally by ELISA (0–24 wpi). Plasma HBsAg-specific ( B ) IgG1, ( C ) IgG2b, and ( D ) IgA levels measured by ELISA. Data are shown as OD 450 . Bars represent median or SEM. Statistics: unpaired t test or two-way ANOVA with Tukey post hoc test.

Article Snippet: For histological and immunofluorescence analyses, formalin-fixed, paraffin-embedded mouse liver sections (5 μm) were stained with hematoxylin and eosin (H&E) or subjected to antigen retrieval and immunostained with anti-HBs (BIOSYNTH, #20-HR20) and anti-HBc (ZETA Corp, #Z2085RL-R) antibodies, followed by Alexa Fluor 488–conjugated anti-rabbit secondary antibody (1:500; Invitrogen).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay

Journal: bioRxiv

Article Title: HEPLISAV-B Breaks Immune Tolerance and Induces HBV Control via CD4 T Cell-Dependent Mechanisms in a Chronic Hepatitis B Mouse Model

doi: 10.64898/2026.03.13.711721

Figure Lengend Snippet: Chronic HBV mice treated with HEPLISAV-B received PBS, anti-CD4, or anti-CD8 antibodies. ( A ) Plasma HBV DNA by qPCR. Plasma ( B ) HBsAg and ( C ) anti-HBs IgG by ELISA. Intrahepatic ( D ) HBV total RNA, ( E ) HBV DNA, and ( F ) AAV DNA. ( G ) Immunofluorescence staining of hepatic HBsAg and HBcAg with ( H,I ) quantification. Data are mean ± SEM. Statistics: two-way ANOVA with Tukey post hoc test.

Article Snippet: For histological and immunofluorescence analyses, formalin-fixed, paraffin-embedded mouse liver sections (5 μm) were stained with hematoxylin and eosin (H&E) or subjected to antigen retrieval and immunostained with anti-HBs (BIOSYNTH, #20-HR20) and anti-HBc (ZETA Corp, #Z2085RL-R) antibodies, followed by Alexa Fluor 488–conjugated anti-rabbit secondary antibody (1:500; Invitrogen).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining

Journal: bioRxiv

Article Title: HEPLISAV-B Breaks Immune Tolerance and Induces HBV Control via CD4 T Cell-Dependent Mechanisms in a Chronic Hepatitis B Mouse Model

doi: 10.64898/2026.03.13.711721

Figure Lengend Snippet: HEPLISAV-B–treated chronic HBV mice received PBS or anti-CD40L antibody. Plasma ( A ) HBsAg and ( B ) anti-HBs IgG measured by ELISA. ( C–E ) Immunofluorescence staining and quantification of hepatic HBsAg and HBcAg. Data are mean ± SEM. Statistics: unpaired t test or two-way ANOVA with Tukey post hoc test.

Article Snippet: For histological and immunofluorescence analyses, formalin-fixed, paraffin-embedded mouse liver sections (5 μm) were stained with hematoxylin and eosin (H&E) or subjected to antigen retrieval and immunostained with anti-HBs (BIOSYNTH, #20-HR20) and anti-HBc (ZETA Corp, #Z2085RL-R) antibodies, followed by Alexa Fluor 488–conjugated anti-rabbit secondary antibody (1:500; Invitrogen).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining